PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15894011-7	2005	This increase in CVR by endothelin-1 was not affected by L-NAME and was reversed by meclofenamate or L-NAME + meclofenamate.	NG-Nitroarginine Methyl Ester	101-107	endothelin-1	Capra hircus	24-36	
15259791-3	2003	After L-NAME treatment, the reductions of coronary flow by both peptides were augmented, and this augmentation was about two times higher for endothelin-1 than for vasopressin.	NG-Nitroarginine Methyl Ester	6-12	endothelin-1	Capra hircus	142-154	
15607496-7	2004	The effects of endothelin-1 and vasopressin on CVC were decreased by approximately 50% during nontreated hypertension, and this was abolished by L-NAME and was not affected by meclofenamate.	NG-Nitroarginine Methyl Ester	145-151	endothelin-1	Capra hircus	15-27	
12193126-5	2002	In this case, ET-1 (0.01-0.3 nmol) also decreased coronary vascular conductance, which was similar in N(G)-nitro-L-arginine methyl ester-treated hypertension that observed in normotension.	NG-Nitroarginine Methyl Ester	102-136	endothelin-1	Capra hircus	14-18	
8960882-15	1996	With L-NAME, the reductions of coronary blood flow by endothelin-1 were potentiated (P < 0.05), and those by IRL 1620 were not changed (P > 0.05).	NG-Nitroarginine Methyl Ester	5-11	endothelin-1	Capra hircus	54-66